Modificación de mecanismos asociados a la patogénesis y evolución de aneurismas de aorta abdominal mediante inhibición de factor Xa con rivaroxabán

Abstract

Abdominal aortic aneurysms (AAA) remain one of the leading mortality causes in western countries, being the fifteenth most common cause of death globally. No effective medical therapy is currently available for the prevention and treatment of AAA. However, the etiopathogenesis of this disease has been thoroughly studied and it is well known the key role of proteolytic activity, inflammation and oxidative stress in the development, growth and rupture of AAAs. Factor Xa (FXa) is one of the most important components of the coagulation cascade, but it also has a direct effect on the vascular wall, modifying the energetic metabolism and increasing the oxidative stress and inflammation at that level. Rivaroxaban, a FXa inhibitor, has proved to have anti-inflammatory and anti-oxidative stress effects in diseases that share pathogenic mechanisms with AAAs, such as atherosclerosis. However, the effect of this drug in human AAAs has not been assessedyet...